Increased plasma proteasome chymotrypsin-like activity in patients with advanced solid tumors

Tumor Biology

Volumn 32, Issue 4, 2011, Pages 753-759

  Hempel, Dominika ^a   Wojtukiewicz, Marek Z ^a   Kozłowski, Leszek ^b   Romatowski, Jacek ^b   Ostrowska, Halina ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b University Teaching Hospital in Bia ystok   (Poland)

Author keywords

Cancer; Carcinoembryonic antigen levels; Chymotrypsin like activity; Fluorogenic peptide substrate; Plasma proteasome ChT L activity

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CHYMOTRYPSIN; CHYMOTRYPSIN LIKE ACTIVITY; PROTEASOME; PROTEASOME ALPHA6 SUBUNIT; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; EARLY CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECTUM CANCER; SOLID TUMOR; STOMACH CANCER;

EID: 80052310276     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0177-2     Document Type: Article

References (33)

1. Coux O, Tanaka K, Goldberg AL. Structure and functions of the 20S and 26S proteasomes. Annu Rev Biochem. 1996;65:801-47. (Pubitemid 26255262)
2. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev. 2002;82:373-428. (Pubitemid 34654457)
3. Kloetzel PM, Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr Opin Immunol. 2004;16:76-81. (Pubitemid 38198120)
4. Baumeister W, Dahlmann B, Hergel R, Kopp F, Kuehn L, Pfeifer G. Electron microscopy and image analysis of the multicatalytic proteinase. FEBS Lett. 1988;241:239-45. (Pubitemid 19005014)
5. Groll M, Dietzel L, Lowe J, Stock D, Bochtler M, Bartnik H, et al. Structure of 20S proteasome from yeast at 2,4Å resolution. Nature. 1997;386:463-71. (Pubitemid 27164066)
6. Orlowski M, Wilk S. Catalytic activities of the 20S proteasome, a multicatalytic proteinase complex. Arch Biochem Biophys. 2000;383:1-16.
7. Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol. 2001;8:739-58. (Pubitemid 32752454)
8. Almond JB, Cohen GM. The proteasome: a novel target for cancer therapy. Leukemia. 2002;16:433-43. (Pubitemid 34449723)
9. Adams J, Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Investig. 2004;22:304-11. (Pubitemid 38725184)
10. Stapnes C, Doskeland AP, Hatfield K, Ersvaer E, Ryningen A, Lorens JB. The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Brit J Haematol. 2007;136:814-28. (Pubitemid 46348414)
11. Kuhn DJ, Chen Q, Voorhees PM, Strader JS, Shenk KD, Sun CM, et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against pre-clinical models of multiple myeloma. Blood. 2007;110:3281-90. (Pubitemid 350106321)
12. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer. 2004;4:349-60. (Pubitemid 38579481)
13. Ludwig H, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer. 2005;104:1794-807. (Pubitemid 41513161)
14. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol. 2006;46:189-213. (Pubitemid 43271188)
15. Vink J, Cloos J, Kaspers GJL. Proteasome inhibition as novel treatment strategy in leukaemia. Br J Haematol. 2006;134:253-62. (Pubitemid 43990787)
16. Crawford LJ, Walker B, Irvine AE. Proteasome inhibitors: a therapeutic strategy for haematological malignancy. Front Biosci. 2008;13:4285-96. (Pubitemid 351599684)
17. Ma W, Kantarjian H, O'Brien S, Jilani I, Zhang X, Estrov Z, et al. Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia. Cancer. 2008;112:1306-12. (Pubitemid 351429746)
18. Ma W, Kantarjian H, Bekele B, Donahue AC, Zhang X, Zhang ZJ, et al. Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clin Cancer Res. 2009;15:3820-6.
19. Ma W, Kantarjian H, Zhang X, Wang X, Estrov Z, O'Brien S, et al. Ubiquitin-proteasome system profiling in acute leukemias and its clinical relevance. Leuk Res. 2011;35:526-33.
20. Ostrowska H, Hempel D, Holub M, Sokolowski J, Kloczko J. Assessment of circulating proteasome chymotrypsin-like activity in plasma of patients with acute and chronic leukemias. Clin Biochem. 2008;41:1377-83.
21. Wang JY, Lu CY, Chu KS, Ma CJ, Wu DC, Tsai HL, et al. Prognostic significance of pre- and postoperative serum carcinoembryonic antigen levels in patients with colorectal cancer. Eur Surg Res. 2007;39:245-50. (Pubitemid 47000372)
22. Bradford MM. A rapid and sensitive method for the quantization of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-54.
23. Meng L, Mohan R, Kwok BH, Elofsson M, Sin N, Crews CM. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA. 1999;96:10403-8. (Pubitemid 29422570)
24. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T. Nature. 1970;227:680-5.
25. Lavabre-Bertrand T, Henry L, Carillo S, Guiraud I, Ouali A, Dutaud D, et al. Plasma proteasome level is a potential marker in patients with solid tumors and hemopoietic malignancies. Cancer. 2001;92:2493-50.
26. Dutaud D, Aubry L, Henry L. Development and evaluation of a sandwich ELISA for quantification of the 20S proteasome in human plasma. J Immunol Methods. 2002;260:183-93. (Pubitemid 34132884)
27. Stoebner PE, Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S, Dandurand M, et al. High plasma proteasome levels are detected in patients with metastatic malignant melanoma. Br J Dermatol. 2005;152:948-53. (Pubitemid 40704935)
28. Henry L, Lavabre-Bertrand T, Douche T, Uttenweiler-Joseph S, Fabbro-Peray P, Monsarrat B, et al. Diagnostic value and prognostic significance of plasmatic proteasome level in patients with melanoma. Exp Dermatol. 2010;19:1054-9.
29. Heubner M, Wimberger P, Dahlmann B, Kasimir-Bauer S, Kimmig R, Peters J, et al. The prognostic impact of circulating proteasome concentrations in patients with epithelial ovarian cancer. Gynecol Oncol. 2011;120:233-8.
30. Henry L, Lavabre-Bertrand T, Vercambre L, Ramos J, Carillo S, Guiraud I, et al. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. Gut. 2009;58:833-8.
31. Wada M, Kosaka M, Saito S, Sano T, Tanaka K, Ichihara A. Serum concentration and localization in tumor cells of proteasomes in patients with hematologic malignancy and their pathophysiologic significance. J Lab Clin Med. 1993;121:215-23. (Pubitemid 23073128)
32. Jakob C, Egerer K, Liebisch P, T rkmen S, Zavrski I, Kuckelkorn U, et al. Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood. 2007;109:2100-3.
33. Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S, et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008;15:3433-9.